ArticleInternational journal of clinical oncology2025

The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study.

Satoru Taguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.